ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its proprietary antibody-drug conjugate
(ADC) technology, today announced that the following presentations by
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Morgan Stanley Global Healthcare Conference9:10 am ET, September 11 in New York, NY
Stifel Nicolaus 2013 Healthcare Conference11:30 am ET, September 12 in Boston, MA
The webcasts will be accessible live through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s proprietary ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The most advanced compound using ImmunoGen's Targeted Antibody Payload (TAP) technology, Kadcyla ®, is marketed in the US by Genentech, a member of the Roche Group, and undergoing regulatory review in the European Union and Japan. ImmunoGen has four wholly owned clinical-stage compounds, with additional compounds in the clinic through partnerships. More information about ImmunoGen can be found at www.immunogen.com. Kadcyla ® is a trademark of Genentech.